secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0001193125-22-044916
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q4 revenue $186.5M (+72% YoY); FY 2022 guidance $800-830M (19-24% growth)
--------------------------------------------------------------------------------

- Q4 revenue $186.5M (+72% YoY, organic +69%); GAAP EPS $0.50, adjusted EPS $0.81.
- FY 2021 revenue $670.5M (+83% YoY); GAAP EPS $2.24, adjusted EPS $3.06.
- FY 2022 revenue guidance $800-830M (19-24% growth); adjusted EPS guidance $3.21-$3.30.
- Base business contributed 66% of FY revenue; Filtration segment grew ~130% for the year.
- Completed acquisition of BioFlex Solutions; cash $603.8M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312522044916/0001193125-22-044916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312522044916/d317056d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-044916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer